Press Releases

01.10.2025

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

01.06.2025

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.20.2024

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

12.19.2024

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

12.17.2024

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

12.12.2024

Pfizer Declares First-Quarter 2025 Dividend

12.12.2024

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

12.10.2024

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

12.10.2024

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

12.05.2024

Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

11.20.2024

Pfizer Announces New Chief Scientific Officer and President, Research & Development

11.20.2024

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors